Drug Trial Radar · NCT04521179
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Dec 7, 2020
Primary completion
Jan 12, 2022
Study completion May 22, 2023
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Peking University
- First posted
- Aug 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase II,multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.
Conditions
- HER2-positive Solid Tumors
Interventions
KN026 combinationDrug
30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR )Time frame: Throughout the duration of the study; up to 2 years
- Duration of response (DOR)Time frame: Throughout the duration of the study; up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.